Colin Hislop
Colin is the latest addition to the Juvena team having joined the Company on May 1st 2025 as the SVP Clinical Development. He brings with him over 36-years of drug development experience with both small and large molecules across multiple therapeutic areas, many of which were in orphan diseases. Over the course of his career Colin has been involved in early and late-stage clinical development as well as the successful prosecution of multiple drug approvals. Most recently Colin was SVP Clinical Development and Operations for Eiger BioPharmaceuticals where he helped lead the successful prosecution of an NDA (2020) and MAA (2022) for lonafarnib to treat an ultra-rare genetic disease called Hutchinson-Guilford Progeria Syndrome. Prior to Eiger Colin was Chief Medical Officer at Versartis Inc, and before that SVP and Chief Medical Officer at Anthera Pharmaceuticals, helping to take the Company public in 2010. His industry career began with Eily Lilly & Company in the UK, before moving on to increasingly more senior positions with Procter & Gamble Pharmaceuticals, CV Therapeutics and Peninsula Therapeutics.
Colin was educated in the UK where he obtained an undergraduate degree in Medical Biochemistry from the University of Surrey and his medical degree from the Middlesex Hospital Medical School, University of London.
Learn more about Colin
LinkedIn
